Loading organizations...
Loading organizations...
Innovative biopharmaceuticals developing antibody-based cancer treatments.
TORL BioTherapeutics has raised $412.0M across 3 funding rounds.
TORL BioTherapeutics has raised $412.0M in total across 3 funding rounds.
TORL BioTherapeutics has raised $412.0M in total across 3 funding rounds.
TORL BioTherapeutics's investors include Rebecca Luse, Avidity Partners, Bristol Myers Squibb, Goldman Sachs, Perceptive Advisors, RA Capital Management, UC Investments, Vertex Ventures HC, Amit Sinha, Alexandria Venture Investments, Cowen Healthcare Investments, Deep Track Capital.
TORL BioTherapeutics has raised $412.0M across 3 funding rounds. Most recently, it raised $96.0M Series C in October 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 7, 2025 | $96.0M Series C | ||
| Apr 10, 2024 | $158.0M Series B | Rebecca Luse | Avidity Partners, Bristol Myers Squibb, Goldman Sachs, Perceptive Advisors, RA Capital Management, UC Investments, Vertex Ventures HC |
| Apr 13, 2023 | $158.0M Series B | Amit Sinha | Alexandria Venture Investments, Bristol Myers Squibb, Cowen Healthcare Investments, Deep Track Capital, OCV Partners, Perceptive Xontogeny Venture Fund, UC-RNT Fund, Vertex Ventures HC |